BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kuenzig ME, Benchimol EI, Lee L, Targownik LE, Singh H, Kaplan GG, Bernstein CN, Bitton A, Nguyen GC, Lee K, Cooke-Lauder J, Murthy SK. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. J Can Assoc Gastroenterol. 2019;2:S17-S33. [PMID: 31294382 DOI: 10.1093/jcag/gwy055] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 D'Amico F, Tasopoulou O, Fiorino G, Zilli A, Furfaro F, Allocca M, Sileri P, Spinelli A, Peyrin-Biroulet L, Danese S. Early Biological Therapy in Operated Crohn's Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience. Inflamm Bowel Dis 2022:izac110. [PMID: 35640113 DOI: 10.1093/ibd/izac110] [Reference Citation Analysis]
2 M’koma AE. Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview. Medicina 2022;58:567. [DOI: 10.3390/medicina58050567] [Reference Citation Analysis]
3 Hirsch RD, Keung C, Con D, Vasudevan A, Van Langenberg DR, Niewiadomski O. Direct health care costs of managing perianal Crohn's Disease in a population based cohort. Scand J Gastroenterol 2021;:1-7. [PMID: 34932436 DOI: 10.1080/00365521.2021.2016944] [Reference Citation Analysis]
4 Anne Shafer L, Shaffer S, Witt J, Nugent Z, Bernstein CN. IBD Disability Index Is Associated With Both Direct and Indirect Costs of Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab248. [PMID: 34636400 DOI: 10.1093/ibd/izab248] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kuźnicki P, Neubauer K. Emerging Comorbidities in Inflammatory Bowel Disease: Eating Disorders, Alcohol and Narcotics Misuse. J Clin Med 2021;10:4623. [PMID: 34640641 DOI: 10.3390/jcm10194623] [Reference Citation Analysis]
6 Kelm M, Germer CT, Schlegel N, Flemming S. The Revival of Surgery in Crohn's Disease-Early Intestinal Resection as a Reasonable Alternative in Localized Ileitis. Biomedicines 2021;9:1317. [PMID: 34680434 DOI: 10.3390/biomedicines9101317] [Reference Citation Analysis]
7 Ueno A, Jijon HB, Peng R, Sparksman S, Mainoli B, Filyk A, Li Y, Wilson S, Novak K, Panaccione R, Hirota S, Dufour A, Lu C, Beck PL. Association of Circulating Fibrocytes With Fibrostenotic Small Bowel Crohn's Disease. Inflamm Bowel Dis 2021:izab157. [PMID: 34428284 DOI: 10.1093/ibd/izab157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Gargallo-Puyuelo CJ, Laredo V, Gomollón F. Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era? Front Med (Lausanne) 2021;8:681907. [PMID: 34336887 DOI: 10.3389/fmed.2021.681907] [Reference Citation Analysis]
9 Sassaki LY, Miszputen SJ, Kaiser Junior RL, Catapani WR, Bafutto M, Scotton AS, Zaltman C, Baima JP, Ramos HS, Faria MAG, Gonçalves CD, Guimaraes IM, Flores C, Amarante HMBS, Nones RB, Parente JML, Lima MM, Chebli JM, Ferrari MLA, Campos JF, Sanna MGP, Ramos O, Parra RS, da Rocha JJR, Feres O, Feitosa MR, Caratin RF, Senra JT, Santana GO. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil. World J Gastroenterol 2021; 27(23): 3396-3412 [PMID: 34163120 DOI: 10.3748/wjg.v27.i23.3396] [Reference Citation Analysis]
10 Chung WS, Chung S, Hsu CY, Lin CL. Risk of Inflammatory Bowel Disease Following Appendectomy in Adulthood. Front Med (Lausanne) 2021;8:661752. [PMID: 34150801 DOI: 10.3389/fmed.2021.661752] [Reference Citation Analysis]
11 Morris GA, McNicol M, Boyle B, Donegan A, Dotson J, Michel HK, Maltz RM. Increasing Biosimilar Utilization at a Pediatric Inflammatory Bowel Disease Center and Associated Cost Savings: Show Me the Money. Inflamm Bowel Dis 2021:izab110. [PMID: 34037215 DOI: 10.1093/ibd/izab110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
12 Dheri AK, Kuenzig ME, Mack DR, Murthy SK, Kaplan GG, Donelle J, Smith G, Benchimol EI. Shifting health care use from hospitalizations and surgeries to outpatient visits in children with inflammatory bowel disease: a population-based cohort study from Ontario, Canada. J Crohns Colitis 2021:jjab095. [PMID: 34019625 DOI: 10.1093/ecco-jcc/jjab095] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Singh S, Qian AS, Nguyen NH, Ho SKM, Luo J, Jairath V, Sandborn WJ, Ma C. Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996-2016. Inflamm Bowel Dis 2021:izab074. [PMID: 33988697 DOI: 10.1093/ibd/izab074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Lee YM, Seo SH, Cho SY, Choi DH, Cheon MW, Kim HY, Youn DH, Pak SC, Son HS, Na CS. Herbal Medicine and Acupuncture Combined Treatment Attenuates Colitis in Rats. Am J Chin Med 2021;49:965-82. [PMID: 33827383 DOI: 10.1142/S0192415X21500464] [Reference Citation Analysis]
15 Osei JA, Peña-sánchez JN, Fowler SA, Muhajarine N, Kaplan GG, Lix LM. Increasing Prevalence and Direct Health Care Cost of Inflammatory Bowel Disease Among Adults: A Population-Based Study From a Western Canadian Province. Journal of the Canadian Association of Gastroenterology 2021. [DOI: 10.1093/jcag/gwab003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Taxonera C, de Andrés-Nogales F, García-López S, Sánchez-Guerrero A, Menchén B, Peral C, Cábez A, Gómez S, López-Ibáñez de Aldecoa A, Casado MÁ, Menchén L. Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain. Expert Rev Pharmacoecon Outcomes Res 2021;:1-11. [PMID: 33615953 DOI: 10.1080/14737167.2021.1880324] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Naseer M, Poola S, Ali S, Samiullah S, Tahan V. Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going? Curr Clin Pharmacol. 2020;15:216-233. [PMID: 32164516 DOI: 10.2174/1574884715666200312100237] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
18 Mcneill RP, Barclay ML. Cost-effectiveness of therapeutic drug monitoring in inflammatory bowel disease. Current Opinion in Pharmacology 2020;55:41-6. [DOI: 10.1016/j.coph.2020.09.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Richard L, Noller G, Derrett S, Sullivan T, Doolan-Noble F, McCombie A, Schultz M, Ho C, Stokes T. Patients' accounts of living with and managing inflammatory bowel disease in rural Southern New Zealand: a qualitative study. BMJ Open 2020;10:e041789. [PMID: 33184085 DOI: 10.1136/bmjopen-2020-041789] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Borren NZ, Paulides E, Frinack JL, Olson RN, Willrich MAV, van der Woude CJ, Ananthakrishnan AN. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study. Dig Dis Sci 2020. [PMID: 33037969 DOI: 10.1007/s10620-020-06645-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
21 Khafipour A, Eissa N, Munyaka PM, Rabbi MF, Kapoor K, Kermarrec L, Khafipour E, Bernstein CN, Ghia JE. Denosumab Regulates Gut Microbiota Composition and Cytokines in Dinitrobenzene Sulfonic Acid (DNBS)-Experimental Colitis. Front Microbiol 2020;11:1405. [PMID: 32670246 DOI: 10.3389/fmicb.2020.01405] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Smits LJT, Pauwels RWM, Kievit W, de Jong DJ, de Vries AC, Hoentjen F, van der Woude CJ; LADI study group. Lengthening adalimumab dosing interval in quiescent Crohn's disease patients: protocol for the pragmatic randomised non-inferiority LADI study. BMJ Open 2020;10:e035326. [PMID: 32461297 DOI: 10.1136/bmjopen-2019-035326] [Reference Citation Analysis]
23 Beard JA, Click BH. The burden of cost in inflammatory bowel disease: a medical economic perspective. Curr Opin Gastroenterol 2020;36:310-6. [PMID: 32398566 DOI: 10.1097/MOG.0000000000000642] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
24 Targownik LE, Kaplan GG, Witt J, Bernstein CN, Singh H, Tennakoon A, Aviña Zubieta A, Coward SB, Jones J, Kuenzig ME, Murthy SK, Nguyen GC, Peña-Sánchez JN, Benchimol EI. Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis. Am J Gastroenterol 2020;115:128-37. [PMID: 31895723 DOI: 10.14309/ajg.0000000000000503] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
25 Murthy SK, Begum J, Benchimol EI, Bernstein CN, Kaplan GG, McCurdy JD, Singh H, Targownik L, Taljaard M. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut 2020;69:274-82. [PMID: 31196874 DOI: 10.1136/gutjnl-2019-318440] [Cited by in Crossref: 80] [Cited by in F6Publishing: 63] [Article Influence: 40.0] [Reference Citation Analysis]
26 Kaplan GG, Ma C, Seow CH, Kroeker KI, Panaccione R. The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta. J Can Assoc Gastroenterol 2020;3:234-42. [PMID: 32905124 DOI: 10.1093/jcag/gwz044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
27 Windsor JW, Kaplan GG. Evolving Epidemiology of IBD. Curr Gastroenterol Rep. 2019;21:40. [PMID: 31338613 DOI: 10.1007/s11894-019-0705-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 16.3] [Reference Citation Analysis]
28 Mathias H, Heisler C, Morrison J, Currie B, Phalen-Kelly K, Jones J. Examining the Association Between Referral Quality, Wait Time and Patient Outcomes for Patients Referred to an IBD Specialty Program. J Can Assoc Gastroenterol 2020;3:154-61. [PMID: 32671324 DOI: 10.1093/jcag/gwz002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]